Hemab Therapeutics Holdings, Inc. COAG
38.85 USD -0.30 (-0.77%)
As ofNov 19, 2026, 12:22 PM EST
37.91 Day range 39.58
23.00 52-week range 55.42
- YTD
- +14.26%
- 1 year
- +14.26%
News
benzinga.com Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript Hemab Therapeutics Hldgs (NASDAQ:COAG) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent.
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…benzinga.com LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 LifeSci Capital initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $65.
benzinga.com Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaSingle-arm design with a 24-week run-in followed by 48 weeks…
benzinga.com Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today…
